A phase 2 study of CV301 in combination with Tecentriq® (atezolizumab) in patients with locally advanced or metastatic urothelial carcinoma (mUC), or bladder cancer

Trial Profile

A phase 2 study of CV301 in combination with Tecentriq® (atezolizumab) in patients with locally advanced or metastatic urothelial carcinoma (mUC), or bladder cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Atezolizumab (Primary) ; CV 301 (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 According to a Bavarian Nordic media release, this study is anticipated to initiate in the first half of 2018.
    • 14 Mar 2017 New trial record
    • 10 Mar 2017 According to a Bavarian Nordic media release, this study is anticipated to initiate around the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top